Biomarkers Market Size, Share, and Trends 2025 to 2034

Biomarkers Market Size and Forecast 2025 to 2034

The global biomarkers market size was estimated at USD 82.30 billion in 2024 and is anticipated to reach around USD 318.76 billion by 2034, expanding at a CAGR of 14.50% from 2025 to 2034. 

Biomarkers Market Key Takeaways

• North America has held a revenue share of more than 46% in 2024.
• By type, the safety segment has accounted highest revenue share in 2024.
• By application, the drug discovery and development segment will dominate the market in 2024.
• By disease, the cancer segment captured a biggest revenue share of in 2024.

U.S. Biomarkers Market Size and Growth 2025 to 2034

The U.S. biomarkers market size was evaluated at USD 26.08 billion in 2024 and is predicted to be worth around USD 107.12 billion by 2034, rising at a CAGR of 15.20% from 2025 to 2034.

North America doninated the biomarkers market in 2024. The research report covers key trends and prospects of biomarkers products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, biomarkers market is conquered by North America owing to high incidence of cancer and existence of state-of-the-art healthcare infrastructure.

Several prominent players are widely adopting strategies, such as mergers and acquisitions, new product development, investment, and collaboration, to strengthen their position in the industry. For instance, in January 2023, Tempus announced a prospective study in collaboration with AstraZeneca that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). According to the American Cancer Society, in the U.S., the second-most common cancer is lung cancer, and approximately 13% of people diagnosed with lung cancer have SCLC.

• In October 2024, University of Nevada, Las Vegas (UNLV) received a USD 3.2 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop a biomarker observatory that will capture and categorize emerging information on blood tests, brain scans, and digital devices that help diagnose and monitor Alzheimer's disease.

Asia Pacific is expected to expand at a rapid pace during the forecast period. The growth of the region is attributed to the increasing investment in advancing healthcare infrastructure, growing incidence of chronic diseases, increasing demand for personalized medicine, increasing research on the use of biomarkers in the early detection of cancer, and a supportive government framework. For instance, in March 2025, LuNGS Alliance, an initiative led by the Cancer Research and Statistics Foundation (CRSF), announced free Lung NGS (Next Generation Sequencing) biomarker testing for lung cancer patients across India. This initiative is backed by AstraZeneca, Pfizer, and Roche, with 4baseCare serving as the official lab partner. The initiative aims to drive awareness about precision oncology as an essential, accessible, and affordable treatment plan for lung cancer treatment.

Key market Insights

Biomarkers have presented a major boost for early detection of cancer which can be a crucial development in the field of cancer diagnostics. Early detection can be a major advantage in the treatment and management of cancer. Biomarkers are vital as molecular markers of the physiological state of a cell at a definite time. Active genes, their corresponding protein products, and supplementary organic compounds produced by the cell generate these markers. As a regular cell progresses through the intricate process of transformation into a cancerous state, biomarkers can prove vital for the screening of early cancer and individuals at risk of evolving cancer. Consistent, non-invasive examinations for the early recognition of cancer improve the likelihoods for successful treatment and preclude the usage of an invasive biopsy.

Biomarkers Market Growth Factors

• Rising incidences of cancer
• Increasing focus on establishment of biomarker-based diagnostic methods
• Growing number of contract research organizations
• High incidence of chronic ailments
• Increasing research on use of biomarkers in early detection of cancer
• Rapidly expanding applications of biomarkers in diagnostics
  

Market Scope

Type Insights

Safety Biomarkers segment contributed the highest market share in 2024 Safety Biomarkers segment recorded the prime market share in the global biomarkers market by type in 2024. Increasing use in the process of drug discovery is the major reason for high market share of safety biomarkers. Other factors such as increasing investment in research and development to develop new diagnostic procedures is expected to increase the usage of the safety biomarkers over the estimate period.

The efficacy biomarkers are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.

Disease Insights

Cancer segment has held the largest market share in 2024. Cancer is one of the most widely studied disorder in the world. Constant research in the cancer field has revealed that, use of biomarkers in early detection of the deadly disease can be a turning point in cancer management. Strong product pipeline of major manufacturers related to cancer biomarkers is expected to further boost the popularity of biomarkers in cancer management.

Neurological Diseases segment will expand at a significant CAGR during the forecast time-frame.

Application Insights

Drug Discovery and Development segment generated the major market share in 2024. The use of biomarkers is on a constant rise in drug discovery and development majorly due to the advantages offered by biomarkers to scaleup the clinical development stage. These factors contribute to the growth of drug discovery and development segment.

Biomarkers Market Companies

• Bio-Rad Laboratories, Inc.
• Qiagen
• Epigenomics AG
• Abbott
• Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Johnson & Johnson Services, Inc.
• Abbott
• Siemens
• Thermo Fisher Scientific, Inc.

Recent Developments

• In September 2024, Scientists in Chhattisgarh introduced India’s first-ever biomarker kit, which could transform the way Covid-19 severity is predicted and managed. Developed by a team at the Multi-Disciplinary Research Unit (MRU) of Dr Bhimrao Ambedkar Hospital in Raipur. This innovation offers early detection of severe COVID-19 cases, promising to enhance patient outcomes and optimise healthcare resources.
• In October 2024, MEDiC Life Sciences, a Silicon Valley biotech startup, announced that it had entered a research collaboration with Hanmi Pharmaceutical, a pioneer biopharma company in Korea. In this collaboration, MEDiC will use its MCAT platform to identify cancer biomarkers for one of Hanmi’s clinical assets.
• In July 2024, Biogen Inc., Beckman Coulter, Inc. announced a collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and commercialize new tests for tau pathology in Alzheimer’s disease (AD).

Segments Covered In the Report

By Type

• Validation
• Efficacy
• Safety

By Disease

• Neurological Diseases
• Cancer
• Immunological Diseases
• Cardiovascular Diseases
• Others

By Application

• Personalized Medicines
• Drug Discovery & Development
• Diagnostics
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa